Clinical Trial Update: Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating immunogenicity and safety of GSK Bio's HPV vaccine 580299 in healthy women aged 9-25; completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Papillomavirus

Drugs mentioned

• HPV vaccine (580299) (Human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 1 | Status: COMPLETED | Results posted: 2014-04-17